This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
Zealthy para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A virtual-care program with insurance-assisted brand access and one- or three-month compounded supply options. Public material advertises semaglutide from $151 and tirzepatide from $216 monthly, but any membership or coordination fee must be added.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)
- Formats reviewed
- Injection · Oral medicine
- Funding routes
- Private pay · Insurance support
- Service features
- Coaching · Clinician support · Switching pathway · Home delivery
- Access check
- Confirm current state access
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 3 medicine rows · 4 open checks
Recurring cost breakdown
- Compounded semaglutide advertised from $151/month.
- Compounded tirzepatide advertised from $216/month.
- One- and three-month supply options can produce different total charges.
- Any Zealthy membership, coordination, insurance, lab, or delivery charge must be confirmed and added.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Compounded semaglutide | Supply/formulation shown in plan | Not FDA-approved | From $151/month |
| Compounded tirzepatide | Supply/formulation shown in plan | Not FDA-approved | From $216/month |
| Brand GLP-1 pathway | Oral or injectable as covered | FDA-approved brand | Potential insurance copay; not guaranteed |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- Multi-state care is advertised; state-specific clinician and pharmacy access varies.
- The public FAQ should be checked for the exact product and patient state.
Clinician access and follow-up cadence
- Virtual evaluation and ongoing care-team messaging are advertised.
- A single live-visit and refill cadence was not publicly confirmed across all plans.
Pharmacy and fulfillment
- Cash compounded medication is shipped; brand prescriptions may use covered pharmacy channels.
- The named pharmacy by formulation/state is not published in the reviewed FAQ summary.
Insurance and prior authorization
- Zealthy advertises insurance coordination and prior-authorization help for brand medication.
- A cited reduction to a low copay is an example, not a coverage guarantee.
Cancellation, refund, and commitment
- One- and three-month purchases have different practical commitments.
- Confirm membership cancellation separately from a prepaid or pharmacy-processed medication order.
Labs, monitoring, and dose management
- A universal included lab panel was not confirmed.
- Clinical requirements vary by treatment and history.
Maintenance and switching
- Both insurance and cash paths can support ongoing care, but changing between them may change product and pharmacy.
- Confirm existing dose acceptance and next-fill timing before transferring.
Program snapshot
Membership plus treatment
Profiled support: Ongoing clinician access, Coaching or behavior support.
Cash pay · Insurance help
Confirm whether a specific medication route uses benefits and what happens after a denied authorization.
Verify before purchase
Pharmacy depends on the selected route; obtain its name before the first shipment.
What the advertised program may include
- Clinical evaluation
- Care-team messaging
- Coaching tools
- Medication access when prescribed
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Ongoing clinician access
- Coaching or behavior support
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- All-in recurring total including membership
- Named pharmacy by route
- Universal lab schedule
- Public fixed follow-up cadence
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Insurance and cash access model
Supply options and current starting medication prices